[Edaily Reporter Kim Ji-wan] On the 2nd, companies in the domestic pharmaceutical and biotech industry drew market attention for their successive achievements, including clinical progress, expanded production, and major technology exports.
Pharmaceutical and biotech sector index on the 2nd. (Source: KG Zeroin MP Doctor)
Bibozon Pharmaceutical hit the daily price limit as it began additional production, driven by the expanding adoption of its non-narcotic analgesic, Anaprazu, in hospitals. Prestige BioPharma raised expectations for its development ahead of the entry into Phase 2a clinical trials for its pancreatic cancer antibody drug candidate ‘PBP1510’ and an upcoming presentation at a global academic conference. OscoTech continued its upward momentum by licensing its autoimmune disease candidate ‘Sebidoplenib’ to U.S.-based Azios in a deal worth 1 trillion won.
to expand the supply of its non-narcotic analgesic
,
Anaprazu.
According to KG Zeroin’s MP DOCTOR on the same day, Vivzon Pharmaceutical closed at 2,830 won, up 650 won (29.82%) from the previous trading day. The market interprets the decision to expand hospital adoption of Anapraz and increase production as having stimulated investor sentiment.
Bibozon Pharmaceutical announced that it decided to produce an additional 120,000 vials of Anapraz to secure sufficient supply as prescriptions from medical institutions have been rapidly increasing recently. This production decision was made as the domestic supply originally secured was depleted faster than expected. Production will be handled by Huiyi Pharmaceutical in China, a manufacturing partner. Huiyi Pharmaceutical is a company with experience in producing injectables and a production system based on Good Manufacturing Practice (GMP) standards.
Anapra-ju is a non-narcotic analgesic developed in-house by Vivzon Pharmaceutical. It is characterized by reduced risks of addiction and respiratory depression compared to existing narcotic analgesics. It recently garnered attention after a researcher-initiated clinical trial conducted by a team at Samsung Seoul Hospital confirmed pain relief effects comparable to those of narcotic analgesics.
Hospital adoption of Anapra Injection is also expanding. Anapra Injection recently passed the review of the pharmacy committees at major tertiary hospitals, including Samsung Seoul Hospital and Severance Hospital in Sinchon. Building on this, the company is expanding its supply scope to include not only general hospitals but also small and medium-sized hospitals with fewer than 300 beds.
Efforts to secure intellectual property rights for Anapraju are also proceeding smoothly. The high-concentration injectable formulation of Anapraju recently received a patent grant decision from the Eurasian Patent Office (EAPO). Additionally, “VVZ-2471,” an oral non-opioid analgesic candidate being developed by Vivzon—an affiliate of Vivzon Pharmaceutical—has received a notice of grant from the European Patent Office (EPO).
A representative from Vivzon Pharmaceuticals stated, “As the adoption of Anapra is expanding, particularly among major hospitals, existing production volumes are being depleted at a faster rate,” adding, “This additional order is a measure to establish a stable supply system and respond to growing market demand.”
The representative added, “We plan to actively respond to demand in the medical field based on a smooth production and supply system.”
“Expectations for New Pancreatic Cancer Drug Grow”… Prestige BioPharma Shares Rise as It Prepares for PBP1510 Phase 2a Trial
#Prestige BioPharma is drawing intense investor interest as it begins full-scale
clinical
development of its pancreatic cancer antibody drug candidate ‘PBP1510’. On that day, Prestige BioPharma closed at 7,140 won, up 610 won (9.34%) from the previous trading day. The market views the progress in PBP1510’s clinical development and plans to present at global conferences as the driving forces behind the stock’s rise.
Prestige BioPharma announced on the 1st that it had submitted an abstract on PBP1510 to the 2026 Annual Meeting of the European Society for Medical Oncology (ESMO) and has begun formulating a follow-up clinical strategy. The results of the safety and efficacy analysis of PBP1510 are scheduled to be presented at this conference. The presentation will be delivered by Dr. King, a medical oncologist at Northwell Health Cancer Institute in the U.S. and the principal investigator of the clinical trial.
PBP1510 is a novel antibody drug that targets PAUF (Pancreatic Adenocarcinoma Upregulated Factor), which is overexpressed in pancreatic cancer. PAUF is known to be involved in cancer growth, metastasis, and immune evasion, making it a promising target for next-generation pancreatic cancer treatments.
The company unveiled preliminary clinical results at ESMO 2025 last year. At the time, it announced that safety had been confirmed in a study involving a total of 32 patients, with no dose-limiting toxicities (DLTs) observed in either the monotherapy or combination therapy groups. Based on data from the ongoing Phase 1 clinical trial, the company is reviewing the appropriate dosage and treatment strategy. Development is proceeding with the goal of entering Phase 2a trials in the second half of this year.
Preparations for subsequent clinical trials are also gaining momentum. The company is establishing an Advisory Board composed of global oncology experts. Led by Dr. King, the principal investigator, key global Key Opinion Leaders (KOLs) and potential principal investigators will participate to finalize the target patient population, clinical endpoints, and dosing strategies.
The company is also pursuing a companion diagnostics business in conjunction with the therapeutic agent. Prestige BioPharma is developing both tumor tissue-based immunohistochemistry (IHC) diagnostic technology and blood-based diagnostic technology, and is pursuing a partnership with a global diagnostics specialist within the year. The company plans to establish a precision medicine system that enables everything from patient selection to treatment response evaluation by combining PAUF-based diagnostic technology with the therapeutic agent.
Meanwhile, regarding recent fluctuations in financial performance, the company explained that these were the result of accounting impairment losses incurred during the valuation of investment shares in subsidiaries. The company stated that these losses do not involve cash outflows and that it is striving to ensure financial soundness through measures such as the revaluation of subsidiary assets.
A company official said, “We are simultaneously advancing the clinical development of PBP1510, global partnering, and our PAUF-based diagnostic business,” adding, “Based on sufficient cash and cash equivalents and a stable financial structure, we will proceed with the development schedule without any setbacks.”
Park So-yeon, Chairwoman of Prestige BioPharma Group. (Photo: Prestige BioPharma)
“1 Trillion Won Technology Export Jackpot”… OscoTech Rises on Sevidoplenib Deal with U.S. Azios
#The news that OscoTech signed a technology transfer agreement worth up to 1 trillion won with a U.S. biopharmaceutical company the previous day served as a tailwind. On this day, OscoTech closed at 42,000 won, up 1,450 won (3.58%) from the previous trading day. Early in the session, the gains widened further as strong buying interest poured in.
Investor attention was focused on the large-scale technology export agreement announced that day. Oskotec announced that it had signed a technology transfer agreement with Agios Pharmaceuticals, a U.S.-based company specializing in rare disease treatments, regarding Cevidoplenib, a candidate drug for autoimmune diseases.
Under the agreement, Agios will secure exclusive rights to the global clinical development and commercialization of Cevidoplenib. Upon signing the agreement, Oskotec will receive a non-refundable upfront payment of $25 million (approximately 37.5 billion won). Including milestone payments tied to future development, approval, and commercialization achievements, the total contract value could reach up to $665 million (approximately 1 trillion won). The company also expects to receive separate royalties linked to sales following the product’s launch.
Sebidoplenib is an oral new drug candidate that selectively inhibits splenic tyrosine kinase (SYK). Discovered through joint research by Oskotec and its subsidiary Genosco, it works by regulating the abnormal activation of immune cells to treat autoimmune diseases.
In particular, the compound has demonstrated development potential, having progressed to global Phase 2 clinical trials for immune thrombocytopenia (ITP) and rheumatoid arthritis (RA). The company explained that the technology fees secured through this agreement will be distributed between Oskotec and Genosco in a 75% to 25% ratio, in accordance with the existing contract structure.
The partner company, Azios, is a U.S. biopharmaceutical firm specializing in rare diseases. Its flagship product, mitapivat, is a treatment for adult thalassemia and PK deficiency that has received approval in major markets such as the U.S. and Europe, and the company is currently pursuing the expansion of its indications.
Yoon Tae-young, CEO of Oskotec, is interviewed by Edaily on the 23rd of last month. (Photo = Oskotec)
Yoon Tae-young, CEO of Oskotec, stated, “Since the completion of the global Phase 2 clinical trial for sevidoplenin, we have been in discussions with numerous overseas pharmaceutical companies regarding technology transfer,” adding, “We determined that Azios, with its competitive edge in the field of rare blood disorders, is the optimal partner to best realize the potential of sevidoplenin.”
He added, “Based on the development capabilities in rare immune diseases that Agios has accumulated, we expect Sevidoplenib to expand its development scope to various indications and grow into a global new drug that provides new treatment options to patients worldwide.”
Amid a continued trend of net redemptions—where redemptions exceed new issuances—in the corporate bond market, Shinhan Investment Securities and GS Entec are set to conduct bookbuilding this week for …
I’ll try just about anything and report back to you. I’m interested in not only new products but also products making a comeback. I avoid simple reviews. I’ll also explain why a product is popular and…
SK Group has announced plans to invest an unprecedented amount of funds—totaling approximately 1,000 trillion won in total project costs alone—to develop South Korea into “Asia’s largest AI infrastruc…
